Targeting public neoantigens for cancer immunotherapy

Nat Cancer. 2021 May;2(5):487-497. doi: 10.1038/s43018-021-00210-y. Epub 2021 May 17.


Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients' tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous patients. Here we review the opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antigens, Neoplasm* / genetics
  • Humans
  • Immunologic Factors / therapeutic use
  • Immunotherapy
  • Mutation
  • Neoplasms* / therapy
  • Oncogenes


  • Antigens, Neoplasm
  • Immunologic Factors